Search
About
Authors:
Address: Departments of Nephrology and General Medicine Pathology, University Medical Center, Albert-Ludwigs-University, Freiburg, Germany Department of Pathology and Neuropathology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany Department of Urology, University Medical Center, Albert-Ludwigs-University, Freiburg, Germany Institute of Pathology, Esslingen, Germany Department of Urology, Hospital Ruit, Ostfildern, Germany Division of Clinical Chemistry, University Medical Center, Albert-Ludwigs-University, Freiburg, Germany Departments ofPathology and Otolaryngology, Katharinen Hospital, Stuttgart, Germany Genomic Medicine Institute, Lerner Research Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Journal:
Publication:
abstract
the etiology and pathogenesis of renal cell carcinoma (RCC) are only partially understood. Key findings in hereditary RCC, which may be site specific or a component of a syndrome, have contributed to our current understanding. Important heritable syndromes of RCC are those associated with pheochromocytoma, especially von Hippel-Lindau disease (VHL) associated with germline VHL mutations, and pheochromocytoma and paraganglioma syndrome (PGL) associated with mutations in one of the four genes (SDHA-D) encoding succinate dehydrogenase. A subset of individuals with SDHB and SDHD germline DNA mutations and variants develop RCC. RCC has never been described as a component of SDHC-associated PGL3. The European-American Pheochromocytoma and Paraganglioma Registry comprises 35 registrants with germline SDHC mutations. A new registrant had carotid body tumor (CBT) and his mother had CBT and bilateral RCC. Blood DNA, paragangliomas, and RCCs were analyzed for mutations and loss-of-heterozygosity (LOH) in/flanking SDHC and VHL. The proband with unilateral CBT had a germline SDHC c.3G>A (p.M1I) mutation. His mutation-positive mother had CBT at age 42, clear cell RCC (ccRCC) at age 68, and papillary RCC (pRCC) at age 69. Both paraganglial tumors showed somatic LOH of the SDHC locus. Both ccRCC and pRCC did not have a somatic SDHC mutation but showed LOH for intragenic and flanking markers of the SDHC locus. LOH was also present for the VHL locus. Our findings suggest that RCC is a component of PGL3. Biallelic inactivation of the SDHC gene may represent a new pathway of pathogenesis of syndromic and nonsyndromic RCC, perhaps of both clear cell and papillary histologies.
Related Articles
Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Genes Chromosomes Cancer. 1998
Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER. Genes Chromosomes Cancer. 1998 Jul; 22(3):200-9.
Parasympathetic paragangliomas are part of the Von Hippel-Lindau syndrome.
J Clin Endocrinol Metab. 2009
Parasympathetic paragangliomas are part of the Von Hippel-Lindau syndrome.
Gaal J, van Nederveen FH, Erlic Z, Korpershoek E, Oldenburg R, Boedeker CC, Kontny U, Neumann HP, Dinjens WN, de Krijger RR. J Clin Endocrinol Metab. 2009 Nov; 94(11):4367-71. Epub 2009 Oct 6.
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.
Lancet Oncol. 2009
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.
van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, Sleddens HF, Derkx P, Rivière J, Dannenberg H, et al. Lancet Oncol. 2009 Aug; 10(8):764-71. Epub 2009 Jul 1.
Review Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2.
J Clin Endocrinol Metab. 2009
Review Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2.
Boedeker CC, Erlic Z, Richard S, Kontny U, Gimenez-Roqueplo AP, Cascon A, Robledo M, de Campos JM, van Nederveen FH, de Krijger RR, et al. J Clin Endocrinol Metab. 2009 Jun; 94(6):1938-44. Epub 2009 Mar 31.
Review Hereditary paragangliomas.
Adv Otorhinolaryngol. 2011
Review Hereditary paragangliomas.
Raygada M, Pasini B, Stratakis CA. Adv Otorhinolaryngol. 2011; 70:99-106. Epub 2011 Feb 24.